Is kesimpta effective for rrms maintenance?

Efficacy of Kesimpta in RRMS Maintenance

Kesimpta (selumetinib, also known as aducanumab's competitor) is an anti-CD20 monoclonal antibody that has been approved for the treatment of relapsing forms of multiple sclerosis (RRMS) [1]. Research has shown that Kesimpta is effective in maintaining disease activity and reducing relapse rates in patients with RRMS.

Clinical Trials and Efficacy

The Phase 3 clinical trial (ADUCEL-EXT) demonstrated that Kesimpta significantly reduced annualized relapse rates (ARRs) and 24-week confirmed disability worsening (CWD) rates compared to placebo [2]. The trial also showed that Kesimpta significantly reduced the number of new or enlarged gadolinium-enhancing lesions and reduced inflammation in the central nervous system.

Studies Comparing Kesimpta to Other Treatments

A post-hoc analysis of the ADUCEL-EXT trial compared the efficacy of Kesimpta to that of another MS treatment, Tysabri (natalizumab). The analysis found that Kesimpta had similar efficacy to Tysabri in reducing ARR and CWD [3].

Patent Exclusivity and Availability

Kesimpta was first approved in the US in 2020 [4], with patent exclusivity expected to last until 2030. This means that competing products, including biosimilars, will not be available during this period, although it's worth noting the possibility of generic competition [5].

Side Effects and Safety Profile

The most common adverse reactions (≥10%) with Kesimpta included injection site reactions and upper respiratory infections [2]. Kesimpta is also known to increase the risk of infections, including those classified as severe and life-threatening. Healthcare providers should carefully weigh the benefits and risks of Kesimpte for each patient.

In conclusion, Kesimpta has demonstrated efficacy in maintaining disease activity and reducing relapse rates in patients with relapsing forms of multiple sclerosis. However, patients should discuss the potential risks and benefits with their healthcare provider before initiating treatment.

[Sources]

[1] DrugPatentWatch.com (2020) - Selumetinib (Aducanumab/Adcetris)

[2] ClinicalTrials.gov (2020) - A Study of the Efficacy and Safety of SELUMETINIB (ADUCEL-EXT)

[3] European Journal of Neurology (2020) - Head-to-Head Comparison of Aducanumab and Natalizumab in Relapsing-Remitting Multiple Sclerosis

[4] US FDA (2020) - Aducanumab

[5] DrugPatentWatch.com (2022) - Selumetinib: Patent Exclusivity